139 related articles for article (PubMed ID: 22607878)
1. Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures.
Sato T; Watanabe H; Tsuganezawa K; Yuki H; Mikuni J; Yoshikawa S; Kukimoto-Niino M; Fujimoto T; Terazawa Y; Wakiyama M; Kojima H; Okabe T; Nagano T; Shirouzu M; Yokoyama S; Tanaka A; Honma T
Bioorg Med Chem; 2012 Jun; 20(12):3756-67. PubMed ID: 22607878
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.
Yoshikawa S; Kukimoto-Niino M; Parker L; Handa N; Terada T; Fujimoto T; Terazawa Y; Wakiyama M; Sato M; Sano S; Kobayashi T; Tanaka T; Chen L; Liu ZJ; Wang BC; Shirouzu M; Kawa S; Semba K; Yamamoto T; Yokoyama S
Oncogene; 2013 Jan; 32(1):27-38. PubMed ID: 22349823
[TBL] [Abstract][Full Text] [Related]
3. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
Ai X; Sun Y; Wang H; Lu S
Amino Acids; 2014 Jul; 46(7):1635-48. PubMed ID: 24658966
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel selective inhibitors for EGFR-T790M/L858R.
Bai F; Liu H; Tong L; Zhou W; Liu L; Zhao Z; Liu X; Jiang H; Wang X; Xie H; Li H
Bioorg Med Chem Lett; 2012 Feb; 22(3):1365-70. PubMed ID: 22227214
[TBL] [Abstract][Full Text] [Related]
5. A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors.
Lin WH; Song JS; Lien TW; Chang CY; Wu SH; Huang YW; Chang TY; Fang MY; Yen KJ; Chen CH; Chu CY; Hsieh HP; Chen YR; Chao YS; Hsu JT
Anticancer Res; 2012 Jan; 32(1):147-51. PubMed ID: 22213300
[TBL] [Abstract][Full Text] [Related]
6. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
[TBL] [Abstract][Full Text] [Related]
7. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
Zhou W; Liu X; Tu Z; Zhang L; Ku X; Bai F; Zhao Z; Xu Y; Ding K; Li H
J Med Chem; 2013 Oct; 56(20):7821-37. PubMed ID: 24053674
[TBL] [Abstract][Full Text] [Related]
8. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.
Kancha RK; Peschel C; Duyster J
J Thorac Oncol; 2011 Feb; 6(2):387-92. PubMed ID: 21252719
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
10. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Ercan D; Choi HG; Yun CH; Capelletti M; Xie T; Eck MJ; Gray NS; Jänne PA
Clin Cancer Res; 2015 Sep; 21(17):3913-23. PubMed ID: 25948633
[TBL] [Abstract][Full Text] [Related]
11. Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
Yang J; Wang LJ; Liu JJ; Zhong L; Zheng RL; Xu Y; Ji P; Zhang CH; Wang WJ; Lin XD; Li LL; Wei YQ; Yang SY
J Med Chem; 2012 Dec; 55(23):10685-99. PubMed ID: 23116168
[TBL] [Abstract][Full Text] [Related]
12. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
Michalczyk A; Klüter S; Rode HB; Simard JR; Grütter C; Rabiller M; Rauh D
Bioorg Med Chem; 2008 Apr; 16(7):3482-8. PubMed ID: 18316192
[TBL] [Abstract][Full Text] [Related]
13. Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
Song X; Liu X; Ding X
J Mol Recognit; 2017 Apr; 30(4):. PubMed ID: 27891677
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
Pawar VG; Sos ML; Rode HB; Rabiller M; Heynck S; van Otterlo WA; Thomas RK; Rauh D
J Med Chem; 2010 Apr; 53(7):2892-901. PubMed ID: 20222733
[TBL] [Abstract][Full Text] [Related]
15. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
Patel H; Pawara R; Surana S
Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Wang X; Zhang T; Sun D; Tong Y; Xu Y; Chen H; Tong L; Zhu L; Zhao Z; Chen Z; Ding J; Xie H; Xu Y; Li H
J Med Chem; 2016 Aug; 59(15):7111-24. PubMed ID: 27396610
[TBL] [Abstract][Full Text] [Related]
17. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
Ahmed M; Sadek MM; Abouzid KA; Wang F
J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
[TBL] [Abstract][Full Text] [Related]
18. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
Qin M; Wang T; Xu B; Ma Z; Jiang N; Xie H; Gong P; Zhao Y
Eur J Med Chem; 2015 Nov; 104():115-26. PubMed ID: 26451770
[TBL] [Abstract][Full Text] [Related]
19. Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations.
Liu B; Bernard B; Wu JH
Proteins; 2006 Nov; 65(2):331-46. PubMed ID: 16927343
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR.
Hegymegi-Barakonyi B; Eros D; Szántai-Kis C; Breza N; Bánhegyi P; Szabó GV; Várkondi E; Peták I; Orfi L; Kéri G
Curr Opin Mol Ther; 2009 Jun; 11(3):308-21. PubMed ID: 19479664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
